Recordati Industria Chimica e Farmaceutica S.p.A. (BIT:REC)
Italy
· Delayed Price · Currency is EUR 52.80
+1.15 (2.23%)
May 30, 2025, 5:36 PM CET
Revenue by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Specialty & Primary Care | 1.52B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care Growth | 8.66% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases | 891.12M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Growth | 20.82% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Uro-Oncology | 405.90M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urology and Uro-Oncology Growth | 28.55% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular | 392.76M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cardiovascular Growth | 7.35% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal | 224.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Gastrointestinal Growth | 2.38% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cough and Cold | 127.68M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Cough and Cold Growth | -4.25% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Treatment Areas | 311.33M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Treatment Areas Growth | -0.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endocrinology | 335.03M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Endocrinology Growth | 28.34% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Metabolic and Other Areas | 265.36M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Metabolic and Other Areas Growth | 0.10% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology | 290.74M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Oncology Growth | 37.52% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Chemicals | 60.16M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Pharmaceutical Chemicals Growth | 11.47% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanidip | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanidip Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanipress | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Zanipress Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urorec | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Urorec Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Livazo | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Livazo Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drugs for Rare Diseases | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Drugs for Rare Diseases Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Seloken/Logimax | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Seloken/Logimax Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Corporate Products | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Corporate Products Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| OTC | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| OTC Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Local Product Portfolios | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Local Product Portfolios Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Other Product Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eligard | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Eligard Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBIT by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Specialty & Primary Care Operating Income | 423.81M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care Operating Income Growth | 4.62% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Operating Income | 223.91M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Operating Income Growth | 33.89% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
EBITDA by Product
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Specialty & Primary Care EBITDA | 523.35M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care EBITDA Growth | 7.56% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases EBITDA | 368.53M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases EBITDA Growth | 20.30% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
Other
Fiscal year is January - December.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2012 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2012 - 2020 |
| Italy Revenue | 340.63M |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Italy Revenue Growth | 4.43% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Revenue | 2.07B |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| International Revenue Growth | 14.37% |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Europe Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Asia and Oceania Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| America Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| America Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Africa Revenue | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Africa Revenue Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Specialty & Primary Care Like-For-Like Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Rare Diseases Like-For-Like Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|
| Total Like-For-Like Growth | - |
Log In |
Log In |
Log In |
Log In | Upgrade
|